GLP-1RA have shown to control HbA1C levels in patients with T2DM alongside alleviating the frequently existing comorbids, HTN and dyslipidaemia in combination with SGLT2 inhibitors (115)
Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy
Safety results show which side effects occurred and how often participants stopped treatment
doi: 10.1007/s13300-020-00951-6 49 PackerMButlerJFilippatosGSJamalWSalsaliASchneeJet al
In contrast, GLP-/GIP dual agonists, while controlling blood sugar, can more comprehensively regulate lipid metabolism and reduce the risk of cardiovascular diseases [138,139]
Not just because of what it does in trials, although that part is genuinely historic, but because of whats happening around it